Neuphoria Therapeutics (NEUP) Institutional Ownership $8.40 +0.20 (+2.44%) As of 04:00 PM Eastern Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Neuphoria Therapeutics (NASDAQ:NEUP)CurrentInstitutional OwnershipPercentage15.90%Number ofInstitutional Buyers(last 12 months)3TotalInstitutional Inflows(last 12 months)$57.60KNumber ofInstitutional Sellers(last 12 months)0 Get NEUP Insider Trade Alerts Want to know when executives and insiders are buying or selling Neuphoria Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Neuphoria Therapeutics Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails4/17/2025Cyndeo Wealth Partners LLC10,000$58K0.0%N/A0.569% 2/14/2025Jane Street Group LLC13,311$46K0.0%N/A0.817% 2/14/2025Lynx1 Capital Management LP45,806$157K0.1%N/A2.810% (Data available from 1/1/2016 forward) NEUP Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of NEUP shares? During the previous two years, the following institutional investors and hedge funds held shares of Neuphoria Therapeutics shares: Lynx1 Capital Management LP ($157K), and Cyndeo Wealth Partners LLC ($58K), Jane Street Group LLC ($46K).Learn more on Neuphoria Therapeutics' institutional investors. What percentage of Neuphoria Therapeutics' stock is owned by institutional investors? 15.90% of Neuphoria Therapeutics' stock is owned by institutional investors. Learn more on NEUP's institutional investor holdings. Which institutional investors have been buying Neuphoria Therapeutics' stock? The following institutional investors have purchased Neuphoria Therapeutics' stock in the last 24 months: Lynx1 Capital Management LP ($45.81K), Jane Street Group LLC ($13.31K), and Cyndeo Wealth Partners LLC ($10K). How much institutional buying is happening at Neuphoria Therapeutics? Institutional investors have bought a total of 69,117 shares in the last 24 months. This purchase volume represents approximately $57.60K in transactions. Related Companies ALGS Institutional Ownership PDSB Institutional Ownership ANVS Institutional Ownership RENB Institutional Ownership KRON Institutional Ownership VTVT Institutional Ownership ATNM Institutional Ownership INMB Institutional Ownership CELU Institutional Ownership SNTI Institutional Ownership This page (NASDAQ:NEUP) was last updated on 7/24/2025 by MarketBeat.com Staff From Our PartnersElon Just Fired the IRS Agents Targeting Your SavingsElon Musk just fired 6,700 IRS agents — and exposed a war on your retirement. While D.C. scrambles to regai...Priority Gold | SponsoredWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredTrump’s Endgame? (R.I.P. China)Tucked inside a Silicon Valley factory, a bold new tech is quietly emerging—one that could ignite a $12 trilli...Brownstone Research | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredBREAKING: The House just passed 3 pro-crypto bills!Experts Believe Altcoin Season is Here! With this new legislation in effect, crypto experts across the coun...Crypto 101 Media | SponsoredBitcoin Beats Gold — But This Coin Could Beat Them BothBitcoin just hit a record high—but it’s not the top crypto play right now. Crypto analyst Juan Villaverde, ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neuphoria Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neuphoria Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
